Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Foreword
Nature Reviews Cancer 8, 577 (1 August 2008) | doi:10.1038/nrc2461
Limiting supply
Abstract
The use of agents that modulate tumour angiogenesis has led to improvements in patient care, and tumour angiogenesis remains an important area for cancer research. As more anti-angiogenic agents proceed through clinical development, it is important to consider what we now know about the effects these agents have on the tumour vasculature and what aspects of tumour angiogenesis remain to be elucidated.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
